News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Can AstraZeneca PLC (AZN) Live Up To CEO's Growth Plans?



5/21/2014 8:44:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

It appears that Pfizer’s attempt to acquire AstraZeneca (AZN) for roughly $120 billion has failed. The AZN Board of Directors has rejected the offer and Pfizer’s CEO appears to be reluctant to try for a hostile takeover. Part of the AZN Board’s desire to remain independent stems from its belief that AZN’s growth prospects are excellent. Indeed, AZN CEO, Pascal Soriot, has said that AZN ‘s revenues can grow to $45 billion by 2023, up from $25.7 billion last year.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES